Selected article for: "cc international license and disease example"
Author: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Title: Network-based Drug Repurposing for Human Coronavirus
  • Document date: 2020_2_5
    • ID: b4mdiont_57
    Snippet: Owing to lack of the complete drug target information (such as the molecular 'promiscuity' of drugs), the dose-response and dose-toxicity effects for both repurposable drugs and drug combinations cannot be identified in current network models. For example, Mesalazine, an approved drug for inflammatory bowel disease, is . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the.....
    Document: Owing to lack of the complete drug target information (such as the molecular 'promiscuity' of drugs), the dose-response and dose-toxicity effects for both repurposable drugs and drug combinations cannot be identified in current network models. For example, Mesalazine, an approved drug for inflammatory bowel disease, is . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • bowel disease and cc NC International license: 1
    • bowel disease and dose response: 1, 2
    • bowel disease and drug target: 1, 2, 3, 4, 5, 6
    • bowel disease and inflammatory bowel disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • bowel disease and International license: 1
    • cc NC International license and dose toxicity: 1
    • cc NC International license and drug combination: 1
    • cc NC International license and drug target: 1, 2
    • cc NC International license and inflammatory bowel disease: 1
    • cc NC International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC International license and network model: 1, 2, 3
    • current network model and network model: 1, 2
    • dose response and drug combination: 1
    • dose response and drug target: 1, 2, 3
    • dose response and inflammatory bowel disease: 1, 2
    • dose response and International license: 1, 2
    • dose toxicity and drug combination: 1, 2
    • dose toxicity and drug target: 1, 2, 3
    • dose toxicity and International license: 1